BridgeBio Pharma Shares Outstanding 2018-2026 | BBIO
BridgeBio Pharma shares outstanding history from 2018 to 2026. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- BridgeBio Pharma shares outstanding for the quarter ending March 31, 2026 were 0.195B, a 2.44% increase year-over-year.
- BridgeBio Pharma 2025 shares outstanding were 0.192B, a 2.93% increase from 2024.
- BridgeBio Pharma 2024 shares outstanding were 0.186B, a 14.3% increase from 2023.
- BridgeBio Pharma 2023 shares outstanding were 0.163B, a 10.39% increase from 2022.
|
BridgeBio Pharma Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025 | 192 |
| 2024 | 186 |
| 2023 | 163 |
| 2022 | 147 |
| 2021 | 144 |
| 2020 | 118 |
| 2019 | 105 |
| 2018 | 62 |
| 2017 | 31 |
|
BridgeBio Pharma Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2026-03-31 | 195 |
| 2025-12-31 | 192 |
| 2025-09-30 | 192 |
| 2025-06-30 | 191 |
| 2025-03-31 | 190 |
| 2024-12-31 | 186 |
| 2024-09-30 | 189 |
| 2024-06-30 | 188 |
| 2024-03-31 | 179 |
| 2023-12-31 | 163 |
| 2023-09-30 | 163 |
| 2023-06-30 | 161 |
| 2023-03-31 | 153 |
| 2022-12-31 | 147 |
| 2022-09-30 | 148 |
| 2022-06-30 | 147 |
| 2022-03-31 | 146 |
| 2021-12-31 | 144 |
| 2021-09-30 | 147 |
| 2021-06-30 | 147 |
| 2021-03-31 | 139 |
| 2020-12-31 | 118 |
| 2020-09-30 | 118 |
| 2020-06-30 | 117 |
| 2020-03-31 | 118 |
| 2019-12-31 | 105 |
| 2019-09-30 | 117 |
| 2019-06-30 | 93 |
| 2019-03-31 | 92 |
| 2018-12-31 | |
| 2018-09-30 | 61 |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |